このアイテムのアクセス数: 0

このアイテムのファイル:
このアイテムは一定期間後に公開されます。
公開日については,アイテム画面の「著作権等」でご確認ください。
タイトル: 膀胱温存治療が可能であったpT1 plasmacytoid variant 膀胱癌の1例
その他のタイトル: A Case of PT1 Plasmacytoid Variant Bladder Cancer Treated by Bladder Conserving Therapy
著者: 木村, 博子  KAKEN_name
植村, 祐一  KAKEN_name
恵, 謙  KAKEN_name
福澤, 重樹  KAKEN_name
著者名の別形: Kimura, Hiroko
Uemura, Yuichi
Megumi, Yuzuru
Fukuzawa, Shigeki
キーワード: pT1 bladder cancer
Plasmacytoid variant
Bladder conservation
発行日: 30-Sep-2018
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要 = Acta urologica Japonica
巻: 64
号: 9
開始ページ: 369
終了ページ: 372
抄録: Plasmacytoid variant bladder cancer is a highly malignant subtype associated with a high propensity for invasion, metastasis and poor prognosis. Among approximately 100 reported cases, most were diagnosed at an advanced stage and only 10 were diagnosed at a non-muscle-invasive stage. Due to the limited data on clinical features of non-muscle-invasive plasmacytoid variant bladder cancer, its treatment has not been established. We report a long-surviving patient with pT1 plasmacytoid variant bladder cancer in whom the bladder was conserved after detailed pathological examinations of the transurethral resection (TUR) specimen and intensive follow-up. A 65-year-old man presented with macroscopic hematuria. Cystoscopy revealed a nodular tumor 11 millimeters in diameter and no metastasis was observed on computed tomography. The histopathological diagnosis of the TUR specimen was pT1 plasmacytoid variant urothelial carcinoma of the bladder. Microvascular invasion was not found by immunohistochemical staining and histopathological examination of the specimen from the second TUR indicated no residual cancer. The patient strongly desired bladder conservation and additionally underwent intravesical instillation therapy with 40 mg of mitomycin C weekly for 6 consecutive weeks. Follow-up cystoscopy demonstrated 3 small papillary tumors 12 months after intravesical instillation therapy, but histopathologically, the recurrent tumors were pTa with pTis urothelial carcinomas without plasmacytoid components. To treat pTis disease, he subsequently underwent intravesical BCG instillation therapy. The plasmacytoid variant bladder cancer has not recurred for 26 months since the initial diagnosis. Non-muscle-invasive and localized plasmacytoid variant bladder cancer may be treated with bladder conserving therapy.
著作権等: 許諾条件により本文は2019/10/01に公開
DOI: 10.14989/ActaUrolJap_64_9_369
URI: http://hdl.handle.net/2433/234835
PubMed ID: 30369228
出現コレクション:Vol.64 No.9

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。